Management of rHuEPO resistance in CRF patients: a clinical protocol at Winthrop-University Hospital.
An inadequate response to recombinant human erythropoietin (rHuEPO) therapy may be attributable to many underlying causes, with the major cause being iron deficiency. Since improved rHuEPO response can improve quality of life in end-stage renal disease (ESRD) patients, rHuEPO resistance should be investigated and corrected whenever possible. This article will discuss the Winthrop-University Hospital's continuous quality improvement (CQI) initiative that was developed to improve recognition and treatment of rHuEPO resistance.
Trenkle
J A
JA
Winthrop-University Hospital in Mineola, NY, USA.
D000465:Algorithms; D000740:Anemia / Q000209:etiology* / Q000628:therapy*; D019090:Case Management; D002985:Clinical Protocols; D004351:Drug Resistance; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D010353:Patient Education as Topic; D012307:Risk Factors; D017749:Total Quality Management / Q000458:organization & administration
D004921:Erythropoietin